Table 1.

Clinical Data, Transplantation Data, and BATs and Stem Cell Doses

Patient	Sex	Age, yr	M Protein	Previous Chemotherapy	Disease Status at SCT	Risk Status	BATs Dose, 109	Stem Cell Dose, 106/kg	Current Disease Status	Days to Engraftment	TTP Post- SCT, mo	Survival Post-SCT, mo	Maintenance Therapy
1	F	66	IgG	(B + D) × 2	VGPR	Int	24	6	REL	11	6.4	26.7*	Revlimid
2	M	41	IgG	(L + D) × 4	CR	ND	30	7.58	uCR	13		69.30	Revlimid
3	F	54	IgA	(B, dox, D) × 6	PR	High	20	10.26	REL	17	26.2	66.93	Revlimid
4	F	49	IgG	(B, ex, L) × 3	PR	High	20	14	REL->SD	23	3.3	64.90	Revlimid
5	M	59	IgA	(L + D) × 4	CR	Low	20	7.89	**REL-alloBMT	17	15.8	63.67	Revlimid
6	F	40	IgA	(B + dox, D) × 3	VGPR	High	30	7.17	REL	13	42.4	63.97	Revlimid
7	M	66	IgG	(B + D) × 6	PR	ND	20	20.87	uCR	21		62.73	Revlimid
8	F	66	IgG	(B+ TI + D × 3	PR	ND	20	8.18	uCR	12		62.57	Revlimid
9	F	66	IgG	(B + D) × 4	PR	ND	20	7.96	uCR	18		62.50	Revlimid
10	M	62	IgA	(B + D) × 8	VGPR	Low	20	11.7	REL	16	14.8	57.67	No maintenance
11	M	57	IgG	(B + D) × 3	VGPR	Low	30	7.56	REL	18	22.3	56.90	No maintenance
12	M	53	Non-S	(T, B + D + T, B + D)	CR	Low	30	5.05	uCR	14		56.50	No maintenance
Median		58									15.8	62.6

B indicates bortezomib; VGPR, very good partial remission; Int, intermediate risk; L, lenalidomide; D, dexamethasone; CR, complete remission based on bone marrow biopsy; ND, not determined owing to the lack of cytogenetics at the time of diagnosis; uCR, complete remission based on lack of serum MM protein detected because bone marrow biospies were not part of the standard of care at the institution; dox, doxorubicin; PR, partial remission; BMT, bone marrow transplantation; T, thalidomide; Non-S, nonsecretory.

Bold text indicate the patients who received booster infusions.

^*Patient expired from progressive disease.

^**Underwent allogeneic SCT while in PR.